Mega Genomics Limited Issues Profit Warning for FY2025

Key Points for Investors

• Significant Revenue Growth Expected:
  Mega Genomics Limited anticipates its revenue for the year ended 31 December 2025 will be in the range of RMB240.0 million to RMB250.0 million, showing a substantial increase from RMB164.2 million reported for the year ended 31 December 2024.
• Sharp Decline in Profit Attributable to Owners:
  Despite the strong revenue growth, profit attributable to owners of the Group is expected to drop significantly to approximately RMB25.0 million to RMB28.0 million for 2025, compared to RMB45.0 million in 2024.
• Reasons for Divergence in Revenue and Profit Performance:
  The company attributes the expected increase in revenue to effective strategies such as expanding its product range, diversifying its product portfolio, and optimizing its product mix. However, profit is projected to decrease mainly due to recognized credit impairment losses and additional expenses incurred for the resumption of trading.

Critical Information for Shareholders

• Profit Warning Issued:
  This announcement serves as an official profit warning by Mega Genomics Limited. The anticipated decline in profit, despite revenue growth, is a crucial piece of price-sensitive information that could impact share values.
• Unaudited Figures:
  The financial figures disclosed are based on the Board’s preliminary assessment of unaudited consolidated management accounts. These numbers are subject to change as they have not yet been reviewed, confirmed, or audited by the company’s auditors or audit committee.
• Upcoming Financial Results:
  The company is in the process of finalizing its annual results for the year ended 31 December 2025, with the official results announcement expected to be published on 31 March 2026.
• Caution Urged for Investors:
  Shareholders and potential investors are strongly advised to exercise caution when dealing in the shares of Mega Genomics Limited in light of this profit warning and pending audited results.

Additional Details

• The Board of Directors consists of Dr. Yu Rong, Ms. Lin Lin, and Ms. Jiang Jing as executive directors; Ms. Guo Meiling as non-executive director; and Dr. Zhang Ying, Mr. Jia Qingfeng, and Dr. Xie Dan as independent non-executive directors.
• The announcement was authorized by Ms. Lin Lin, Executive Director and Chairperson, and issued on 20 March 2026 in Hong Kong.
• The company is incorporated in the Cayman Islands with limited liability and is listed on the Hong Kong Stock Exchange under stock code 6667.

Implications for Share Price

The divergence between revenue growth and profit decline, especially the substantial decrease in profit attributable to owners, is material and may influence investor sentiment and the company’s share price. The market may react negatively to the profit warning, particularly as the company indicates increased costs and credit impairment losses despite a robust top-line performance.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should refer to the company’s official announcements and consult with professional advisers before making any investment decisions. The financial data presented are based on unaudited management accounts and are subject to adjustment.

View MEGA GENOMICS Historical chart here